| [1] |
Hanahan D,Weinberg RA.The hallmarks of cancer[J].Cell,2000,100(1):57-70.
|
| [2] |
Cai H,Liu YH,Yin TJ,et al.Advances in the targeted therapy of tumor-associated fibroblasts[J].J China Pharm Univ,2018,49(1):20-25.
|
| [3] |
Han X,QI XL,Wu ZH.Advances in self-assemblied DNA nanocages as drug delivery systems[J].J China Pharm Univ,2017,48(6):663-669.
|
| [4] |
Liu YH,Zhou JP,Huo MR.Advances in the tumor microenvironment-responsive smart drug delivery nanosystem[J].J China Pharm Univ,2016,47(2):125-133.
|
| [5] |
Rink JS,Plebanek MP,Tripathy S,et al.Update on current and potential nanoparticle cancer therapies[J].Curr Opin Oncol,2013,25(6):646-651.
|
| [6] |
Kuperwasser C,Chavarria T,Wu M,et al.Reconstruction of functionally normal and malignant human breast tissues in mice[J].Proc Natl Acad Sci U S A,2004,101(14):4966-4971.
|
| [7] |
Trédan O,Galmarini CM,Patel K,et al.Drug resistance and the solid tumor microenvironment[J]. J Natl Cancer I,2013,99(19):1441-1454.
|
| [8] |
Straussman R,Morikawa T,Shee K,et al.Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion[J].Nature,2012,487(7408):500-504.
|
| [9] |
Mueller MM,Fusenig NE.Friends or foes-bipolar effects of the tumour stroma in cancer[J].Nat Rev Cancer,2004,4(11):839-849.
|
| [10] |
Barenholz Y.Doxil® — The first FDA-approved nano-drug:lessons learned[J].J Control Release,2012,160(2):117-134.
|
| [11] |
Zhang L,Marrano P,Kumar S,et al.Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors[J].Clin Cancer Res,2013,19(21):5972-5983.
|
| [12] |
Silverman JA,Deitcher SR.Marqibo(vincristine sulfate liposome injection)improves the pharmacokinetics and pharmacodynamics of vincristine[J].Cancer Chemoth Pharm,2013,71(3):555-564.
|
| [13] |
Yuan F,Leunig M,Huang SK,et al.Microvascular permeability and interstitial penetration of sterically stabilized(stealth)liposomes in a human tumor xenograft[J].Cancer Res,1994,54(13):3352-3356.
|
| [14] |
Wang L,Li C.pH responsive fluorescence nanoprobe imaging of tumors by sensing the acidic microenvironment[J].J Mater Chem,2011,21(40):15862-15871.
|
| [15] |
Callmann CE, Barback CV, Thompson MP, et al. Therapeutic enzyme-responsive nanoparticles for targeted delivery and accumulation in tumors[J].Adv Mater,2015,27(31):4611-4615.
|
| [16] |
Wu T,Boyer JC,Barker M,et al.A “Plug-and-Play” method to prepare water-soluble photoresponsive encapsulated upconverting nanoparticles containing hydrophobic molecular switches[J].Chem Mater,2013,25(12):2495-2502.
|
| [17] |
Goh PP,Sze DM,Roufogalis BD.Molecular and cellular regulators of cancer angiogenesis[J].Curr Cancer Drug Tar,2007,7(8):743-758.
|
| [18] |
Pàezribes M,Allen E,Hudock J,et al.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J].Cancer Cell,2009,15(3):220-231.
|
| [19] |
Gu GZ,Hu QY,Feng XY,et al.PEG-PLA nanoparticles modified with APT EDB,peptide for enhanced anti-angiogenic and anti-glioma therapy[J].Biomaterials,2014,35(28):8215-8226.
|
| [20] |
Ingber D,Fujita T,Kishimoto S,et al.Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth[J].Nature,1990,348(6301):555-557.
|
| [21] |
Kudelka AP,Levy T,Verschraegen CF,et al.A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix[J].Clin Cancer Res,1997,3(9):1501-1505.
|
| [22] |
Bhargava P,Marshall JL,Rizvi N,et al.A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer[J].Clin Cancer Res,1999,5(8):1989-1995.
|
| [23] |
Segal E,Pan H,Benayoun L,et al.Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances[J].Biomaterials,2011,32(19):4450-4463.
|
| [24] |
Shaked Y,Bocci G,Munoz R,et al.Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose[J].Curr Cancer Drug Tar,2005,5(7):551-559.
|
| [25] |
Shaked Y,Ciarrocchi A,Franco M,et al.Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors[J].Science,2006,313(5794):1785-1787.
|
| [26] |
Schneider M,Tjwa M,Carmeliet P.A surrogate marker to monitor angiogenesis at last [J].Cancer Cell,2005,7(1):3-4.
|
| [27] |
Navarro P,Bueno M,Zagorac I,et al.Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics[J].Cell Rep,2016,15(12):2705-2718.
|
| [28] |
Lin PP, Gires O, Wang DD, et al. Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells[J].Sci Rep,2017,7(1):9789.
|
| [29] |
Liang JL,Xu W,Yin TJ,et al.Advances in the hypoxia-responsive antitumor drug nanocarrier and tumor hypoxia relieve[J].J China Pharm Univ(中国药科大学学报),2018,49(3):255-262.
|
| [30] |
Wang K,Li WF,Xing JF,et al.Preliminary assessment of the safety evaluation of novel pH-sensitive hydrogel[J].Eur J Pham Biopharm,2012,82(2):332-339.
|
| [31] |
Zhang L,Wang Y,Yang Y,et al.High tumor penetration of paclitaxel loaded pH sensitive cleavable liposomes by depletion of tumor collagen I in breast cancer[J].Acs Appl Mater Inter,2015,7(18):9691-9701.
|
| [32] |
Yu L,Jia Y,Xin W,et al.In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly(acryic acid)-cystamine hydrochloride-D-α-tocopherol succinate[J].J Biomat Sci-Polym E,2016,27(17):1729-1747.
|
| [33] |
Zhu S,Niu M,O′Mary H,et al.Targeting of tumor-associated macrophages made possible by PEG-sheddable,mannose-modified nanoparticles[J].Mol Pharm,2013,10(9):3525-3530.
|
| [34] |
Weissleder R,Nahrendorf M,Pittet MJ.Imaging macrophages with nanoparticles[J].Nat Mater,2014,13(2):125-138.
|
| [35] |
Ries CH,Cannarile MA,Hoves S,et al.Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy[J].Cancer Cell,2014,25(6):846-859.
|
| [36] |
Feig C,Jones JO,Kraman M,et al.Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer[J].Proc Natl Acad Sci U S A,2013,110(50):20212-20217.
|
| [37] |
Zhang J,Lei M,Guo S,et al.Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model[J].J Control Release,2014,182(1):90-96.
|
| [38] |
Erez N,Truitt M,Olson P,et al.Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner[J].Cancer Cell,2010,17(2):135-147.
|
| [39] |
Chen D, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.
|
| [40] |
Wolchok JD,Kluger H,Callahan MK,et al.Nivolumab plus ipilimumab in advanced melanoma[J].New Engl J Med,2013,369(2):122-133.
|
| [41] |
Luo Z,Wang C,Yi H,et al.Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo[J].Biomaterials,2015,38:50-60.
|
| [42] |
Reddy ST,Vlies AJVD,Simeoni E,et al.Exploiting lymphatic transport and complement activation in nanoparticle vaccines[J].Nat Biotechnol,2007,25(10):1159-1164.
|
| [43] |
Sagiv-Barfi I,Czerwinski D K,Levy S,et al.Eradication of spontaneous malignancy by local immunotherapy[J].Sci Transl Med,2018,10(426):eaan4488.
|
| [44] |
Ou Y,Guo XL.Tumor stem cells and drug resistance[J].Prog Physiol Sci(生理科学进展),2007,38(2):115.
|
| [45] |
Fiorillo M,Verre AF,Iliut M,et al.Graphene oxide selectively targets cancer stem cells,across multiple tumor types:implications for non-toxic cancer treatment,via “differentiation-based nano-therapy”[J].Oncotarget,2015,6(6):3553-3562.
|
| [46] |
Justilien V,Regala RP,Tseng IC,et al.Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance,tumor initiation and metastatic potential[J].PLos One,2012,7(4):e35040.
|
| [47] |
Ames E,Canter RJ,Grossenbacher SK,et al.NK cells preferentially target tumor cells with a cancer stem cell phenotype[J].J Immunol,2015,195(8):4010-4019.
|
| [48] |
Gao L,Wang H,Nan L,et al.Erythrocyte membrane-wrapped pH sensitive polymeric nanoparticles for non-small cell lung cancer therapy[J].Bioconjugate Chem,2017,28(10):2591-2598.
|
| [49] |
Swami A,Reagan MR,Basto P,et al.Engineered nanomedicine for myeloma and bone microenvironment targeting[J].Proc Natl Acad Sci U S A,2014,111(28):10287-10292.
|
下载:
